What is tesamorelin?
Tesamorelin (trans-3-hexenoyl-GHRH(1-44) amide) is a 44-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH), developed by Theratechnologies. A single N-terminal fatty-acid modification extends its plasma half-life from ~7 minutes (native GHRH) to ~26-38 minutes, enough for once-daily subcutaneous dosing. FDA approved it in 2010 (Egrifta) for HIV-associated lipodystrophy, with the reformulated Egrifta SV (2019) and longer-acting Egrifta WR (2023) extending the lifecycle.
In research-use-only (RUO) protocols, tesamorelin occupies a unique niche: it is the only GHRH analog with large Phase 3 data proving visceral adipose tissue (VAT) reduction without caloric restriction. It is studied for metabolic syndrome, NAFLD/NASH, post-menopausal body composition, and cognitive decline (Baker 2012 showed improved executive function in older adults). Storage is stable lyophilized at 2–8°C; reconstituted in bacteriostatic water, stability reaches ~28 days refrigerated. Lab Peptides France ships every vial with a certified COA (HPLC ≥98%) and traceable batch number.
GHRH mechanism: pulsatile endogenous stimulation
Pituitary GH release
Binds GHRH-R on anterior pituitary somatotrophs, triggering endogenous growth hormone secretion — while preserving the natural pulsatile pattern and negative feedback loops.
IGF-1 cascade
Downstream GH elevates hepatic IGF-1 production. The mediator of most anabolic and lipolytic effects on muscle, bone, and adipose tissue.
VAT-specific lipolysis
Unlike exogenous GH, tesamorelin preferentially mobilizes visceral fat with minimal impact on glucose tolerance — the clinical signature that earned FDA approval.
Tesamorelin is categorically different from direct GH injection: it stimulates the pituitary's own production, which preserves physiological pulsatility and downregulates less insulin sensitivity than exogenous somatropin — a key reason researchers prefer it for long-duration protocols.
Clinical studies LIPO / MATCH
Falutz et al. — NEJM 2007 (LIPO-010)
Phase 3 · n=412Pivotal trial in HIV-infected patients with excess visceral adiposity, 26 weeks of daily subcutaneous tesamorelin 2mg vs placebo. The trial that anchored FDA approval.
- -15.2% visceral adipose tissue (VAT)
- +4.6% lean body mass
- -9.6% triglycerides
Stanley et al. — Lancet HIV 2019 (MATCH)
Phase 4 · Hepatic fat · n=61Randomized trial examining hepatic fat (MRI-PDFF) after 12 months of daily tesamorelin in HIV-infected adults with NAFLD — the first peptide trial to target fatty liver directly.
- -37% hepatic fat (absolute)
- -31% liver fibrosis score (FIB-4)
- 35% achieved NAFLD resolution
Cognitive and cardiovascular extensions — Baker et al. 2012 (Arch Neurol) showed 20 weeks of tesamorelin improved executive function in adults with mild cognitive impairment. Other investigational endpoints include coronary plaque composition and post-menopausal body recomposition — active areas of ongoing research 2024-2026.
Tesamorelin products
Two research formats cover every protocol — pure tesamorelin for GHRH-specific research, and the tesamorelin + ipamorelin dual combo for studies targeting amplified GH pulse amplitude. Each vial is HPLC ≥98%, COA-certified, shipped from France with cold-chain packaging.
Tésamoréline 10mg
PurePure format — GHRH-specific protocols, ~5 days at 2mg daily (LIPO-010 Phase 3 reference dose); at research micro-dose (100-300 µg/day) several weeks of autonomy.
View productTésamoréline 20mg
VolumeVolume format — same molecule, twice the autonomy: long protocols without reordering mid-series.
View productWhy Lab Peptides France
HPLC ≥98% purity, every batch
Third-party HPLC-MS certification. COA downloadable on every product page, batch number traceable. No gray-market powder.
Stocked in France
Cold-chain packaging, discrete neutral boxes, stocked in France (no customs). Dispatches leave Tuesday and Friday, then 2 to 3 business days with Colissimo. Tracking included.
French-speaking support
Team based in Europe, replies under 4h on weekdays. Technical questions, reconstitution guidance, order tracking.
5% automatic cashback
Every paid order credits 5% of its subtotal to your loyalty balance, convertible into a promo code from 5 €. Card, Apple Pay and Google Pay accepted.
Ready to order?
Most popular research format: pure tesamorelin 10mg. At the 2mg/day Phase 3 reference dose (LIPO-010), one vial covers ~5 days — research protocols typically plan multiple vials per cycle.
Order Tesamorelin 10mgFrequently asked questions
Is tesamorelin legal in France?
Yes, as a research compound (RUO) intended exclusively for laboratory use. The Egrifta molecule is FDA-approved as a prescription medicine; in RUO, sale and possession for research are legal, but any human, veterinary, or therapeutic use is strictly prohibited outside the medical channel.
What is the difference between tesamorelin alone and the tesamorelin + ipamorelin combo?
Tesamorelin acts on GHRH receptors. Ipamorelin, on the other hand, is a GHRP (growth hormone-releasing peptide) that acts on ghrelin receptors. Combined, they amplify the GH pulse synergistically (~2-3× each molecule alone) — the reference configuration for studies targeting maximal GH response.
Why tesamorelin over direct GH?
Tesamorelin stimulates endogenous GH production via the pituitary, preserving physiological pulsatility and limiting impact on insulin sensitivity (a known drawback of exogenous somatropin). It also preferentially targets visceral adipose tissue, the clinical signature that earned its FDA approval — an effect absent with GH alone.
How to reconstitute tesamorelin?
Use sterile bacteriostatic water, typical ratio 2ml per 10mg (final concentration 5mg/ml). Slowly inject water against the vial wall, do not shake, let it sit 2 minutes then gently roll. Stable ~28 days at 2–8°C after reconstitution. Full detailed guide on /en/reconstitution-guide.
What is the reference dose in trials?
The Phase 3 pivotal dose (Falutz NEJM 2007, Egrifta) is 2mg/day subcutaneously, administered at bedtime to coincide with the natural nocturnal GH pulse. At this dose, a 10mg vial covers ~5 days of daily protocol — full research cycles (26 weeks per Falutz) require multiple vials.
Do you ship to France? How fast?
Yes. Dispatches leave Tuesday and Friday, then allow 2 to 3 business days with Colissimo. Stocked in France, no customs. Discrete packaging, cold chain preserved, tracking included. Permanent stock on both formats.
Which payment methods do you accept?
Card (Visa, Mastercard, CB), Apple Pay and Google Pay. Every paid order credits 5% of its subtotal to your loyalty balance, convertible into a promo code from 5 €.
Will I receive a Certificate of Analysis (COA)?
Every batch ships with a third-party COA (HPLC-MS, ≥98% purity), downloadable directly from the product page before purchase. Batch number is traceable.